13F Insight
DOSSIER · 13F-HR · Q2 2026

TCG Crossover Management, LLC

$4.2B in tracked AUM across 54 positions as of Q2 2026.

TC
CIK 0001839948 · last filed Jun 30, 2026
Total AUM
$4.2B
as of Q2 2026
Holdings
54
—
positions
Whale Score
65
65
tracked
Activity
—
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of TCG Crossover Management, LLC 13F Filing
Portfolio Overview

TCG Crossover Management, LLC manages a concentrated, high-conviction portfolio totaling approximately $1.52 billion as of the report date September 30, 2025. This represents a significant portfolio expansion of +73.9% (an increase of roughly $645 million) compared to the $875.51 million reported in the previous quarter.

The portfolio is highly concentrated, consisting of only 30 holdings. Th...

Key Holdings

The portfolio exhibits extreme concentration risk, with the top holding comprising nearly 40% of the total assets.

  • ABIVAX SA (ABVX): This is the dominant position, valued at $603.77 million and representing 39.66% of the portfolio. The manager increased this stake by 17.4% (adding $557.44 million in value), signaling a core "high-conviction" bet. This level of concentration suggests the fund views ABIVAX as a potential breakout winner in its therapeutic area.
  • Cogent Biosciences (COGT): The second-largest holding at $97.62 million (6.41% allocation). Despite being a top position, the manager reduced the stake by 2.4% (approx. $47.62 million), suggesting a partial profit-take or risk management strategy on this specific name.
  • Amylyx Pharmaceuticals & Tango Therapeutics: Rounding out the top four, these positions ($84.85M and $71.70M respectively) indicate a strong preference for companies developing novel mechanisms of action for neurodegenerative diseases and oncology.
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
ABVX
ABIVAX SA AMERICAN DEPOSITARY SHARES
$801M6.0M19.2%02
TNGX
TANGO THERAPEUTICS INC
$284M9.1M6.8%03
CGON
CG ONCOLOGY INC
$261M3.7M6.3%04
COGT
COGENT BIOSCIENCES INC
$188M4.9M4.5%05
IMVT
IMMUNOVANT INC
$172M4.5M4.1%06
SYRE
SPYRE THERAPEUTICS INC
$169M1.9M4.1%07
DNTH
DIANTHUS THERAPEUTICS INC
$163M1.7M3.9%08
MIRM
MIRUM PHARMACEUTICALS INC
$124M1.1M3.0%09
ZLAB
ZAI LAB LTD-ADR
$117M6.1M2.8%10
AMLX
AMYLYX PHARMACEUTICALS INC
$112M6.2M2.7%

Filing history

2026Q2Jun 30
$4.2B▲ 19.0%
54 positionsView →2026Q1Mar 31
$3.5B▲ 15.7%
49 positionsView →2025Q4Dec 31
$3.0B▲ 98.5%
43 positionsView →2025Q3Sep 30
$1.5B▲ 73.9%
30 positionsView →2025Q2Jun 30
$876M▲ 19.4%
38 positionsLocked2025Q1Mar 31
$733M▼ 28.4%
38 positionsLocked2024Q4Dec 31
$1.0B▼ 13.3%
38 positionsLocked2024Q3Sep 30
$1.2B▲ 23.0%
36 positionsLocked2024Q2Jun 30
$960M▼ 24.1%
32 positionsLocked2024Q1Mar 31
$1.3B▲ 40.3%
33 positionsLocked2023Q4Dec 31
$902M▲ 32.8%
29 positionsLocked2023Q3Sep 30
$679M▲ 11.4%
26 positionsLocked
Showing 12 of 19